Jane Street Group LLC Has $396,000 Stock Holdings in Annexon, Inc. (NASDAQ:ANNX)

Jane Street Group LLC reduced its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 37.2% during the third quarter, Holdings Channel reports. The institutional investor owned 66,864 shares of the company’s stock after selling 39,601 shares during the period. Jane Street Group LLC’s holdings in Annexon were worth $396,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sandia Investment Management LP bought a new position in shares of Annexon in the 2nd quarter worth $49,000. Victory Capital Management Inc. bought a new position in shares of Annexon in the second quarter valued at $51,000. Principal Financial Group Inc. acquired a new position in shares of Annexon during the second quarter valued at about $56,000. Quarry LP bought a new stake in shares of Annexon during the third quarter worth about $118,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Annexon in the 3rd quarter worth about $154,000.

Annexon Stock Performance

Shares of ANNX opened at $5.05 on Wednesday. The stock has a 50 day moving average of $5.62 and a 200 day moving average of $5.94. The company has a market capitalization of $538.30 million, a price-to-earnings ratio of -4.81 and a beta of 1.11. Annexon, Inc. has a 12 month low of $3.86 and a 12 month high of $8.40.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.80.

Insider Buying and Selling at Annexon

In other Annexon news, EVP Ted Yednock sold 5,408 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total value of $40,073.28. Following the transaction, the executive vice president now directly owns 71,365 shares in the company, valued at $528,814.65. The trade was a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 12.67% of the company’s stock.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.